Analysts at William Blair lifted their Q2 2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. William Blair analyst L.

Apellis Pharmaceuticals has a 1 year low of $19.76 and a 1 year high of $57.85. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Insmed (INSM – Research Report) today and set a price target of $96.00.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Travere Therapeutics (TVTX – Research ...

PE-backed specialty pharma company Kelso Pharma appointed Giovanni Mauri as general manager of its recently acquired Italian ...

A group of biotech CEOs, investors, and patient advocates have urged Senate HELP Committee Chairman Bill Cassidy (R-LA) to ...

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will appeal the decision.

The global Age-Related Macular Degeneration (AMD) Market is poised for significant expansion over the next decade, with its value expected to grow from US$ 11.31 billion in 2023 to US$ 19.72 billion ...